Ganymed's IMAB362 Receives Orphan Drug Designation From FDA and EMA for Pancreatic Cancer
"The granting of this orphan drug designation represents another important milestone for our IMAB362 program", commented Dr. Özlem Türeci, CEO of Ganymed Pharmaceuticals. "There are presently very few therapeutic options for patients suffering from pancreatic cancer. We are excited by the promise that IMAB362 showed in preclinical models of pancreatic cancer and look forward to assessing its therapeutic potential in future clinical trials for this indication."
Orphan drug designation is given to investigational new drugs that are under development for the treatment of life-threatening or very serious diseases that affect fewer than 200,000 patients in the US or less than 5 in 10,000 individuals across Europe. The designation aims to promote the development of innovative drugs for patients with these rare diseases by incentivizing companies with certain benefits such as market exclusivity, tax incentives and waiving of certain regulatory and marketing fees.
IMAB362 is a first-in-class monoclonal antibody selectively binding to the tight junction protein CLDN18.2 which is expressed in approximately 60% of primary and metastatic pancreatic cancers. CLDN18.2 is also expressed in up to 80% of gastroesophageal cancers as well as in other solid tumors. However, CLDN18.2 is absent from the vast majority of healthy tissues. This makes IMAB362 cancer cell selective with little or no effect on healthy cells and reduced risks of side effects. This represents a great advantage over other anticancer therapies which target both cancerous and healthy cells.
GANYMED Pharmaceuticals AG
Ganymed Pharmaceuticals AG is a biopharmaceutical company with the mission of revolutionizing cancer treatment by developing a new class of therapeutic drugs called Ideal Monoclonal Antibodies (IMABs). IMABs are unique in that they are highly selective for proteins which are present on tumor cells, but do not bind to healthy cells. This unmatched tumor cell specificity makes IMABs cancer cell selective allowing them to efficiently kill tumor cells without harming normal healthy tissues. They can thus be administered at optimal dose and have a broad therapeutic window with reduced risks of side effects.
Ganymed's lead program, IMAB362, is in advanced phase II testing for gastroesophageal cancer. IMAB362 binds to the tight junction protein Claudin-18.2 which is expressed in up to 80% gastroesophageal adenocarcinomas, 60% pancreatic tumors as well as in other various solid tumors. Ganymed is also developing IMAB027, a monoclonal antibody targeting GT512 which is absent in healthy adult organs, but is expressed in a wide range of solid cancers, including testicular, ovarian, uterine, and lung cancers. The company plans to initiate clinical studies with IMAB027 in the near future.
Ganymed is a private company that was founded in 2001 as a spin-off from the Universities of Mainz and Zurich. Its majority shareholder is ATS Beteiligungsverwaltung GmbH. Other investors include Future Capital AG, MIG Fonds, First Capital Partner GmbH, and private individuals.
Press releases you might also be interested in
Weitere Informationen zum Thema "Forschung und Entwicklung":
Risiken bei IoT, KI sorgt für Vereinfachungen
Der Machine-Learning-Experte Splunk hat einige Vorhersagen für das kommende Jahr gewagt. So sollen etwa Künstliche Intelligenz (KI ) und maschinelles Lernen den IT-Betrieb deutlich vereinfachen.Weiterlesen